Navigation Links
New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
Date:4/29/2008

Biomarkers to Open the Door to Personalized Medicine and Represents a

Seismic Shift for the Pharma Industry

PHILADELPHIA and LONDON, April 29 /PRNewswire-FirstCall/ -- The Scientific business of Thomson Reuters today announced the launch of a new biomarkers report, "Establishing the Standards in Biomarker Research" which gives a detailed introduction to the world of biomarkers, an overview of the regulatory context surrounding them, and highlights ongoing biomarker research in some of the world's leading Pharma companies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NYTH069LOGO )

Thomson Reuters has chosen to highlight advances in biomarker research because of its capacity to change the way Pharma companies do business. Biomarkers which are blood-based tests, gene sequences or mutations, mRNA expression profiles or tissue proteins, provide unparalleled evidence of the state of an organism, or indicate normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.

"Biomarkers seem destined to prove one of the major drivers of pharmaceutical research and drug development in the 21st century," said Jon Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson Reuters. "For example, the presence of a specific antibody in the blood might indicate a specific infection. Once an association between a biomarker and a disease is clearly established, the one can be used to signal the other, and to a high degree of certainty. As well, changes in the prevalence of a biomarker in the organism can immediately and reliably signpost a patient's response to treatment."

Some pharmaceutical companies are already advancing their research and harnessing the power of biomarkers, which can:
-- Be used to detect the predisposition for disease in a population,

screen for its presence, confirm its diagnosis, assess its severity,

predict its response to available therapies and measure its

clinical course

-- Be used as targets to discover new drugs

-- Be a decisive factor in determining whether or not to continue

research on an entity

-- Show early in the development phase whether an entity could lead to

side effects that should terminate further research

-- Help to make clinical trials more efficient

-- Reduce treatment overheads by optimizing dosages and measuring a

patient's response more quickly and accurately

It is believed that every drug process may have a number of biomarkers associated with it. Most scientists already use a core set of biomarkers, but this is insignificant when compared to the thousands of biomarkers that may exist and have yet to be discovered, documented or quantified. The new Thomson Reuters biomarker report suggests that the disease areas at the forefront of the drive to discover new biomarkers are: cancer, cardiology, neurology, and metabolic, autoimmune and inflammatory diseases.

However, although biomarkers represent the future of drug development, Thomson Reuters analysis has found broad differences in the Pharma industry's approach to them. Some innovators have important biomarker research projects progressing, while many others have yet to attempt any research at all.

In spite of this, biomarkers are clearly at the top of the agenda for regulatory authorities. The FDA has recognized that biomarkers are an area of supreme importance to pharmaceutical innovation and personalized medicine and is seeking to create a new framework for regulatory acceptance. Other agencies, including the EMEA, are engaging with same process. In Japan, the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare, have proposed biomarker development as a national project, and are actively promoting biomarker research.

To read the full report, "Establishing the Standards in Biomarker Research", please register online at: http://scientific.thomson.com/forms/biomarkers/

The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Its authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (NASDAQ: TRIN). For more information, go to http://www.thomsonreuters.com.

CONTACTS

Eoin Bedford

PR Manager

Scientific

+44 (0)207 433 4691

eoin.bedford@thomsonreuters.com


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare
2. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
3. Thomson Healthcare Announces Enhancements to Order Sets Solution
4. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
5. Thomson Scientific Introduces a New Quarterly Report Identifying the Movers and Shakers in the U.S. Generics Industry
6. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
7. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
8. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
9. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
10. Thomson Scientific Takes a Fresh Look at Multiauthor Papers
11. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology: